Get in touch:
+64 21 402 487


Fast-Track Your Due Diligence

Fast Delivery of Investor

Updates and Support



Investor Summary as .pdf

Get Instant Access to

1. The investor pack from Founder and CEO - Dr. Marina Rajič

2. Notifications for real time updates and monthly reports to our investors.

Get | Investor Pack

Marina Rajic


Raising Strategy

Raising our bridge round in Q3/23

  • Commitment to GMP facility, Wellington
  • GMP production ready in 2024 
  • Development milestone: Increase production yield
  • Scale marketing and sales: Sign customers for clinical grade manufacture
  • Next inflection point in Q4/24  Series A.

Back To Top -->|

Market Size

  • Oncology counts for over 60% of total market
  • CAR-T therapies in the global cell and gene therapy market is expected to grow from 82.73% in 2022 to 90.32% by 2030.
  • Five out of six FDA approved CAR-T therapies use lentiviral vectors.

Back To Top -->|

Cell and Gene Therapy TAM

30.8B NZD  in 2022

155.1B NZD by 2030

22.4%  CAGR

Lentiviral Vector Manufacture Market 



11.9%  CAGR

Bridge Round

Raising NZD 3.5M in Q3/23

Our bridge round is an important stepping stone to scale operations, improve technology, and secure contracts, all crucial for meeting the growing demand in the cell and gene therapy sector.
This round enables us to reach key milestones that can significantly increase our companies value & setting the stage for a successful Series A round in 2024 and potential high returns for early investors.

How To Invest

  1. Get your investor pack
  2. Meet the founder
  3. Sign CDA, and receive information memorandum
  4. Complete due diligence 
  5. Close the deal
Estimated time from first registration to closed deal:
3 months

Back To Top -->|

Use Of Funds & Forecast

revenue forecast 1

  • Scaling production capacity from preclinical to clinical-grade.
  • Improving production technology and processes.
  • Developing and securing intellectual property during the bridge round.
use of funds 1
  • Ensuring regulatory compliance
    with all requirements.
  • Securing manufacturing contracts with biotech and pharmaceutical companies
  • Increasing capacity
    with strategic alliances and partnerships.

Investing in New Zealand

There are many benefits for choosing New Zealand.

  • Highly skilled workforce
  • Supportive government
  • Favorable regulatory environment
  • A strong economy
  • An attractive place to work

Overall, New Zealand is an excellent location for biotech CDMOs. The country has a number of advantages that make it an attractive option for companies to develop and manufacture high value biological products.

Trans-Pacific Partnership

New Zealand is a member of the Trans-Pacific Partnership (TPP). Some of our benefits are.

  • Reduced tariffs among member countries
  • Enhanced intellectual property rights
  • Regulatory coherence streamline regulations among member countries
  • Easier access to markets of all member countries
  • Supply chain efficiency
  • The TPP includes provisions that protect foreign investments
  • High labor and environmental standards

Experienced Leadership
Benefit from the expertise of an experienced leadership team. BioViros is backed by Bridgewest Group.

Lab Team
Hannah Pearce
Hannah Pearce, Ph.D.

Biotech Development Scientist

Sofia Grey
Sofia Grey

Process Development Assistant

Isabella Lovalvo
Isabella Lovalvo

Student Intern - Berkeley, California

Ellie Torbati, Ph.D.

Biotech Research Scientist

Marina Rajic, Ph.D.
Marina Rajic, Ph.D.

Founder & CEO

Tom VanCott
Tom VanCott, Ph.D.

Director, Chairman

Saum Vahdat
Saum Vahdat


John Robson
John Robson


Farzad Haerizadeh, Ph.D.
Farzad Haerizadeh, Ph.D.

Scientific Advisor

Stephen Chang, Ph.D.
Stephen Chang, Ph.D.

Scientific Advisor

Rick Hancock
Rick Hancock

Strategic Advisor

BioViros-Brand_IconOnly-Red Consider BioViros as Investment

Action Required

Fund raising for the bridge round will end in August 2023. Get the info.

Get | Investor Pack


Explore our Mission --->|